Clovis Oncology (CLVS) Tops Q4 EPS by 3c

Clovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($1.27), $0.03 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $17.04 million versus the consensus estimate of $20.08 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M